Handel nachbörslich: 2.73 -0.02 -0.73%

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten

Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MyChesCo

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - EIN News

Aptar's N-Sorb accepted into FDA Emerging Technology Program - Investing.com India

Sagefield Capital LP Purchases New Stake in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) - Defense World

Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World

Patterson-UTI Energy Inc [PTEN] is -22.50% lower this YTD. Is it still time to buy? - The DBT News

Market Watch: Applied Dna Sciences Inc (APDN)’s Noteworthy Gain, Closing at 1.25 - The Dwinnex

Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison - Defense World

Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo

Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa

Adicet Bio (NASDAQ:ACET) Rating Reiterated by Wedbush - MarketBeat

Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - Defense World

Adicet Bio's (ACET) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Australia

Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Canada

APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com UK

Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review (APLT) - Seeking Alpha

Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga

Applied Therapeutics Shares Rise as Drug Continues with Priority Review - MarketWatch

Applied DNA Sciences (NASDAQ:APDN) Upgraded to Sell by StockNews.com - Defense World

Ascendis Pharma price target raised to $289 from $264 at Wells Fargo - TipRanks

Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MSN

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - GlobeNewswire

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - Yahoo Finance

UPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com

Doylestown Cancer Pharma Moves Closer to Starting Clinical Testing on Its 3rd Experimental Cancer Treatment - BUCKSCO.Today

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com India

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com Canada

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com UK

APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com

Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MyChesCo

Myelodysplastic Syndrome (MDS) Drugs Market Research Report Explores 2024-2033 | Size, Growth, Demand, Trends - WhaTech

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in July - Defense World

Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World

Q3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC Wainwright - Defense World

Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - Defense World

Wedbush Comments on Aerovate Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:AVTE) - Defense World

Aprea Therapeutics (NASDAQ:APRE) Releases Earnings Results, Beats Estimates By $0.05 EPS - Defense World

Aprea Therapeutics’ (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials - MyChesCo

Aprea Therapeutics (NASDAQ:APRE) Given “Buy” Rating at HC Wainwright - Defense World

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com Canada

APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - MSN

APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com UK

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - wallstreet:online

Aclaris Therapeutics Reports Q2 2024 Financial Results and Updates - MyChesCo

Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? - Simply Wall St

Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Decline in Short Interest - Defense World

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely? - Yahoo Finance

Alltrna Announces Updates to Its Board of Directors - Financial Times

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 13.3% in June - Defense World

Small-Cap Sunday Highlights: Andean Precious Metals, Aadi Bioscience, Aprea Therapeutics, Arc Document Solutions, Curaleaf - The Dales Report

DDR Defective Tumors Industry is Expected to Reach Rapid Growth - openPR

Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Large Drop in Short Interest - Defense World

Savara Inc. Announces Breakthrough in aPAP Treatment with IMPALA-2 Trial Success - MyChesCo

FY2026 EPS Estimates for Aprea Therapeutics, Inc. Increased by Analyst (NASDAQ:APRE) - Defense World

Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright - Defense World

Aprea Therapeutics Hosts Virtual Event on Promising Cancer Therapy - MyChesCo

Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug - MSN

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 - ForexTV.com

Ähnlich wie APRE